About
About Us
Who We Are
Glyvantis Bio is a University College Dublin spin-out, based in Dublin, Ireland.
Our tehnology is set to change pahrmaceutical antibody drug development.
We combine a highly accredited scientific founder with an expert team of drug developers and biotech entrepreneurs who are collectively engaged with top CDMOs.
Key Benefits of Glyvantis Bio technology
is a unique, proven and reproducible cell engineering technology to optimise galactosylation for antibodies to;
- Consistent galactosylation of antibodies with improved clinical profile.
- Eliminates product variability challenges and improves reproducibility in drug manufacturing.
- Allows for the creation of new IP opportunities for existing antibodies coming off patent.
- Allows for the creation of new drugs based on protein backbones of existing antibodies.
- Allows development of antibodies that have failed development due to lack of therapeutic window.